Henan Lingrui Pharmaceutical Future Growth
Future criteria checks 2/6
Henan Lingrui Pharmaceutical is forecast to grow earnings and revenue by 11.5% and 15.5% per annum respectively while EPS is expected to grow by 11.3% per annum.
Key information
11.5%
Earnings growth rate
11.3%
EPS growth rate
Pharmaceuticals earnings growth | 19.1% |
Revenue growth rate | 15.5% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 30 Oct 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 4,518 | 746 | N/A | 787 | 1 |
12/31/2024 | 3,963 | 641 | N/A | 688 | 1 |
3/31/2024 | 3,432 | 614 | 756 | 777 | N/A |
12/31/2023 | 3,311 | 568 | 792 | 813 | N/A |
9/30/2023 | 3,232 | 526 | 847 | 865 | N/A |
6/30/2023 | 3,200 | 512 | 904 | 924 | N/A |
3/31/2023 | 3,108 | 479 | 805 | 830 | N/A |
12/31/2022 | 3,002 | 465 | 808 | 835 | N/A |
9/30/2022 | 2,917 | 440 | 654 | 696 | N/A |
6/30/2022 | 2,841 | 412 | 574 | 622 | N/A |
3/31/2022 | 2,786 | 396 | 637 | 707 | N/A |
12/31/2021 | 2,694 | 362 | 769 | 846 | N/A |
9/30/2021 | 2,635 | 383 | 663 | 741 | N/A |
6/30/2021 | 2,513 | 368 | 688 | 768 | N/A |
3/31/2021 | 2,430 | 346 | 460 | 536 | N/A |
12/31/2020 | 2,332 | 325 | 379 | 451 | N/A |
9/30/2020 | 2,215 | 302 | 367 | 424 | N/A |
6/30/2020 | 2,163 | 288 | 336 | 387 | N/A |
3/31/2020 | 2,068 | 270 | 386 | 428 | N/A |
12/31/2019 | 2,157 | 294 | 391 | 450 | N/A |
9/30/2019 | 2,149 | 292 | 442 | 479 | N/A |
6/30/2019 | 2,118 | 280 | 447 | 493 | N/A |
3/31/2019 | 2,078 | 270 | 413 | 460 | N/A |
12/31/2018 | 2,053 | 243 | 384 | 436 | N/A |
9/30/2018 | 2,139 | 240 | 319 | 420 | N/A |
6/30/2018 | 2,120 | 230 | 223 | 356 | N/A |
3/31/2018 | 1,990 | 223 | 27 | 201 | N/A |
12/31/2017 | 1,849 | 217 | N/A | 106 | N/A |
9/30/2017 | 1,697 | 198 | N/A | 18 | N/A |
6/30/2017 | 1,608 | 381 | N/A | 52 | N/A |
3/31/2017 | 1,513 | 364 | N/A | 107 | N/A |
12/31/2016 | 1,439 | 346 | N/A | 63 | N/A |
9/30/2016 | 1,315 | 365 | N/A | 113 | N/A |
6/30/2016 | 1,225 | 152 | N/A | 100 | N/A |
3/31/2016 | 1,133 | 141 | N/A | 110 | N/A |
12/31/2015 | 1,085 | 132 | N/A | 225 | N/A |
9/30/2015 | 1,006 | 119 | N/A | 251 | N/A |
6/30/2015 | 936 | 115 | N/A | 203 | N/A |
3/31/2015 | 901 | 97 | N/A | 173 | N/A |
12/31/2014 | 826 | 76 | N/A | 124 | N/A |
9/30/2014 | 802 | 75 | N/A | 130 | N/A |
6/30/2014 | 757 | 65 | N/A | 129 | N/A |
3/31/2014 | 718 | 59 | N/A | 130 | N/A |
12/31/2013 | 687 | 105 | N/A | 127 | N/A |
9/30/2013 | 662 | 103 | N/A | 88 | N/A |
6/30/2013 | 617 | 103 | N/A | 46 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600285's forecast earnings growth (11.5% per year) is above the savings rate (2.9%).
Earnings vs Market: 600285's earnings (11.5% per year) are forecast to grow slower than the CN market (24.4% per year).
High Growth Earnings: 600285's earnings are forecast to grow, but not significantly.
Revenue vs Market: 600285's revenue (15.5% per year) is forecast to grow faster than the CN market (14.7% per year).
High Growth Revenue: 600285's revenue (15.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 600285's Return on Equity is forecast to be high in 3 years time